Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract

• Published in: Journal of virology Vol. 93; no. 13
• Main Authors: Goffin, Emeline, Javaux, Justine, Destexhe, Eric, Pretto, Carla D, Spindler, Katherine R, Machiels, Bénédicte, Gillet, Laurent
• Format: Journal Article Web Resource
• Language: English
• Published: United States American Society for Microbiology 01-07-2019
• Subjects: Adenoviridae - immunology; Adenoviridae Infections - immunology; Adenoviridae Infections - prevention & control; Adenovirus Vaccines - immunology; Adenoviruses, Human; Administration, Oral; Animals; Antibodies, Viral - immunology; Disease Models, Animal; Female; Gastrointestinal Tract - immunology; Humans; Immunization; Life sciences; Lung - pathology; Mice; Mice, Inbred BALB C; Microbiologie; Microbiology; Sciences du vivant; Vaccination; Vaccines and Antiviral Agents; Vaccines, Attenuated - immunology; Vaccines, Synthetic - immunology; oral vaccination; mouse model; adenovirus
• ISSN: 0022-538X; 1098-5514; 1098-5514
• DOI: 10.1128/JVI.00237-19

Since the 1970s, replication-competent human adenoviruses 4 and 7 have been used as oral vaccines to protect U.S. soldiers against the severe respiratory diseases caused by these viruses. These vaccines are thought to establish a digestive tract infection conferring protection against respiratory challenge through antibodies. The success of these vaccines makes replication-competent adenoviruses attractive candidates for use as oral vaccine vectors. However, the inability of human adenoviruses to replicate efficiently in laboratory animals has hampered the study of such vectors. Here, we used mouse adenovirus type 1 (MAV-1) in mice to study oral replication-competent adenovirus-based vaccines. We show that MAV-1 oral administration provides protection that recapitulates the protection against homologous respiratory challenge observed with adenovirus 4 and 7 vaccines. Moreover, live oral MAV-1 vaccine better protected against a respiratory challenge than inactivated vaccines. This protection was linked not only with the presence of MAV-1-specific antibodies but also with a better recruitment of effector CD8 T cells. However, unexpectedly, we found that such oral replication-competent vaccine systemically spread all over the body. Our results therefore support the use of MAV-1 to study replication-competent oral adenovirus-based vaccines but also highlight the fact that those vaccines can disseminate widely in the body.
Replication-competent adenoviruses appear to be promising vectors for the development of oral vaccines in humans. However, the study and development of these vaccines suffer from the lack of any reliable animal model. In this study, mouse adenovirus type 1 was used to develop a small-animal model for oral replication-competent adenovirus vaccines. While this model reproduced in mice what is observed with human adenovirus oral vaccines, it also highlighted that oral immunization with such a replication-competent vaccine is associated with the systemic spread of the virus. This study is therefore of major importance for the future development of such vaccine platforms and their use in large human populations.